Release Date: April 23, 2025
Expiration Date: April 23, 2026
Activity Overview
Neovascular AMD (nAMD) can lead to rapid vision loss, arising from fragile, new blood vessels originating in the choroid and growing into the subretinal space, Bruch’s membrane, or the subretinal pigment epithelial (RPE) space. A variety of pathophysiologic changes serve as risk factors for the development of late AMD, which in the dry form is referred to as geographic atrophy (GA), featuring patches of RPE cell dropout that can cause severe vision loss when the fovea is involved. Agents that slow GA progression – avacincaptad pegol and pegcetacoplan – are now approved.
This online educational activity is designed to provide expert perspectives of new and emerging data from clinical trials in patients with GA, with a focus on reviewing the safety data from recent clinical trials and how to apply this data in practice. The program includes a case-based approach to highlight the key messages shared by the expert faculty.
Target Audience
This educational activity is directed primarily toward retinal specialists, comprehensive ophthalmologists, and optometrists involved in the management of patients with geographic atrophy (GA).
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply best practices in addressing patient concerns in the management of GA through appropriate treatment and/or referral strategies
- Outline current evidence regarding adverse clinical events related to treatment of GA
Yasha Modi, MD
Associate Professor of Ophthalmology
Director of Tele-Retina
NYU Langone Health
New York, NY
Disclosures: Consultant; Alcon, Alimera, 4DMT, Abbvie, Eyepoint, Adverum, Neurotech, Eyepoint, Zeiss, Genentech, Regeneron, OPthea, Topcon
Carolyn Majcher, OD, FAAO, FORS
Associate Professor
Director, Residency Programs
Oklahoma College of Optometry
Tahlequah, OK
Disclosures: Consultant: Apellis, Astellas, LENZ Therapeutics, Notal Vision, Optomed, Regeneron, Tarsus, Topcon, Zeiss; Speakers’ Bureau: Apellis, Astellas, Optomed, Regeneron, Zeiss
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC, (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here